| Author | 木浦 勝行| 谷本 安| 田端 雅弘| 金廣 有彦| 上岡 博| 谷本 光音| 渡邊 都貴子| 草野 展周| 小出 典男| |
|---|---|
| Published Date | 2005-05-30 |
| Publication Title | 岡山医学会雑誌 |
| Volume | volume115 |
| Issue | issue1 |
| Content Type | Journal Article |
| JaLCDOI | 10.18926/AMO/47266 |
|---|---|
| FullText URL | 65_6_403.pdf |
| Author | Waseda, Koichi| Tanimoto, Yasushi| Ichiba, Shingo| Miyahara, Nobuaki| Murakami, Toshi| Ochi, Nobuaki| Terado, Michihisa| Nagano, Osamu| Maeda, Yoshinobu| Kanehiro, Arihiko| Ujike, Yoshihito| Tanimoto, Mitsune| |
| Abstract | Bronchiolitis obliterans (BO) is a disease with a poor prognosis, and a key factor that limits long-term survival after allogeneic hematopoietic stem cell transplantation (HSCT). We here report a case of a 31-year woman with acute lymphatic leukemia, which was treated by chemotherapy and HSCT, and consequently developed BO 2 years after HSCT. A non-tuberculous mycobacterial infection occurred and showed gradual exacerbation. She started taking anti-mycobacterial drugs, but lost appetite, felt tired and finally lost consciousness one month after beginning medication. Arterial blood gas revealed marked hypercapnia. Using extracorporeal life support (ECLS), the carbon dioxide concentration was reduced and her consciousness recovered. To our knowledge, this is the first case in which ECLS was successfully used for hypercapnia in a patient with BO. |
| Keywords | extracorporeal life support hypercapnia bronchiolitis obliterans noninvasive positive pressure ventilation |
| Amo Type | Case Report |
| Published Date | 2011-12 |
| Publication Title | Acta Medica Okayama |
| Volume | volume65 |
| Issue | issue6 |
| Publisher | Okayama University Medical School |
| Start Page | 403 |
| End Page | 406 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| Copyright Holders | CopyrightⒸ 2011 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 22189481 |
| Web of Science KeyUT | 000298516900007 |
| Author | Taniguchi, Akihiko| Miyahara, Nobuaki| Nakahara, Atsushi| Takata, Saburo| Sakugawa, Ryo| Nagano, Osamu| Tanimoto, Yasushi| Kanehiro, Arihiko| Kiura, Katsuyuki| Ujike, Yoshito| Tanimoto, Mitsune| |
|---|---|
| Published Date | 2011-12-01 |
| Publication Title | 岡山医学会雑誌 |
| Volume | volume123 |
| Issue | issue3 |
| Content Type | Journal Article |
| JaLCDOI | 10.18926/AMO/51868 |
|---|---|
| FullText URL | 67_5_319.pdf |
| Author | Murakawa, Kiminaka| Sato, Tomoaki| Maeda, Yoshinobu| Kitamura, Yoshihisa| Tanimoto, Mitsune| Sendo, Toshiaki| |
| Abstract | Graft-versus-host disease (GVHD) is a major concern in transplantation patients. Gut GVHD is accompanied by diarrhea, abdominal pain, and/or melena. Although oral treatment with corticosteroids (CSs) is effective in treating gut GVHD, it can cause adverse reactions that affect the entire body. Topical administration of CSs can be effective in treating diseases in which lesions are limited locally, because adverse reactions can then be alleviated. In this study, we examine and discuss an enteric-coated beclomethasone dipropionate (BDP) capsule (BDP-EC) formulated at Okayama University Hospital. The BDP-EC did not dissolve in solution 1 (pH1.2), and began disintegrating in solution 2 (pH6.8) after 5min, with a mean dissolution rate at 15min of 85%. We then used the capsule to treat a patient who developed gut GVHD after allogeneic hematopoietic stem cell transplantation. Clinically, the frequency of diarrhea decreased after BDP-EC administration. In addition, we were able to decrease the prednisolone equivalent dose. Symptoms associated with adverse reactions to BDP were not observed during the hospitalization period. These findings suggest that the administration of BDP-EC in the early stages of gut GVHD may allow a reduction in the initial doses of systemic CSs. |
| Keywords | beclomethasone intestinal graft-versus-host disease enteric-coated capsule in-hospital formulation |
| Amo Type | Case Report |
| Published Date | 2013-10 |
| Publication Title | Acta Medica Okayama |
| Volume | volume67 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 319 |
| End Page | 324 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| Copyright Holders | CopyrightⒸ 2013 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 24145732 |
| Web of Science KeyUT | 000325836100006 |
| Author | Soga, Yoshihiko| Maeda, Yoshinobu| Tanimoto, Mitsune| Ebinuma, Takayuki| Maeda, Hiroshi| Takashiba, Shogo| |
|---|---|
| Published Date | 2013-02 |
| Publication Title | Supportive Care in Cancer |
| Volume | volume21 |
| Issue | issue2 |
| Content Type | Journal Article |
| Author | Ebinuma, Takayuki| Soga, Yoshihiko| Sato, Takamaro| Matsunaga, Kazuyuki| Kudo, Chieko| Maeda, Hiroshi| Maeda, Yoshinobu| Tanimoto, Mitsune| Takashiba, Shogo| |
|---|---|
| Published Date | 2014-06 |
| Publication Title | Supportive Care in Cancer |
| Volume | volume22 |
| Issue | issue6 |
| Content Type | Journal Article |
| Author | Gotoda, Tatsuhiro| Kawano, Seiji| Kono, Yoshiyasu| Miura, Kou| Kanzaki, Hiromitsu| Iwamuro, Masaya| Kawahara, Yoshiro| Tanaka, Takehiro| Yoshino, Tadashi| Shirakawad, Yasuhiro| Tabata, Masahiro| Tanimoto, Mitsune| Okada, Hiroyuki| |
|---|---|
| Published Date | 2016-12-01 |
| Publication Title | Journal of Okayama Medical Association |
| Volume | volume128 |
| Issue | issue3 |
| Content Type | Journal Article |
| JaLCDOI | 10.18926/AMO/54499 |
|---|---|
| FullText URL | 70_4_243.pdf |
| Author | Osawa, Masahiro| Ohashi, Kadoaki| Kubo, Toshio| Ichihara, Eiki| Takata, Saburo| Takigawa, Nagio| Takata , Minoru| Tanimoto, Mitsune| Kiura, Katsuyuki| |
| Abstract | Vandetanib (ZactimaTM) is a novel, orally available inhibitor of both vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) tyrosine kinase. In the present study, a line of transgenic mice with a mouse Egfr gene mutation (delE748-A752) corresponding to a human EGFR mutation (delE746-A750) was established. The transgenic mice developed atypical adenomatous hyperplasia to adenocarcinoma of the lung at around 5 weeks of age and died of lung tumors at approximately 17 weeks of age. In the mice treated with vandetanib (6mg/kg/day), these lung tumors disappeared and the phosphorylations of EGFR and VEGFR-2 were reduced in lung tissues to levels comparable to those of non-transgenic control mice. The median overall survival time of the transgenic mice was 28 weeks in the vandetanib-treated group and 17 weeks in the vehicle-treated group. Vandetanib significantly prolonged the survival of the transgenic mice (log-rank test, p＜0.01); resistance to vandetanib occurred at 20 weeks of age and the animals died from their lung tumors at about 28 weeks of age. These data suggest that vandetanib could suppress the progression of tumors harboring an activating EGFR mutation. |
| Keywords | vandetanib VEGFR EGFR nonsmall cell lung cancer transgenic mouse |
| Amo Type | Original Article |
| Published Date | 2016-08 |
| Publication Title | Acta Medica Okayama |
| Volume | volume70 |
| Issue | issue4 |
| Publisher | Okayama University Medical School |
| Start Page | 243 |
| End Page | 253 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| Copyright Holders | CopyrightⒸ 2016 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 27549668 |
| Web of Science KeyUT | 000384748600003 |
| Author | Yasugi, Masayuki| Takigawa, Nagio| Ochi, Nobuaki| Ohashi, Kadoaki| Harada, Daijiro| Ninomiya, Takashi| Murakami, Toshi| Honda, Yoshihiro| Ichihara, Eiki| Tanimoto, Mitsune| Kiura, Katsuyuki| |
|---|---|
| Published Date | 2014-08-15 |
| Publication Title | Experimental Cell Research |
| Volume | volume326 |
| Issue | issue2 |
| Content Type | Journal Article |
| Title Alternative | Treatment for a non-compliant patient with cancer and epilepsy |
|---|---|
| FullText URL | 126_133.pdf |
| Author | Minami, Daisuke| Ichihara, Eiki| Okabe, Nobuyuki| Yokomichi, Naosuke| Kouge, Noriko| Kajizono, Makoto| Akimoto, Yutaka| Hori, Keisuke| Matsubara, Minoru| Nasu, Junichiro| Tanimoto, Mitsune| Kiura, Katsuyuki| Matsuoka, Junzi| |
| Abstract | A 58-year-old man with cervical esophageal cancer and a history of epilepsy was treated with chemoradiotherapy from May of 2013. When tube feeding was initiated due to aspiration pneumonitis, the patient showed a degree of irritability that affected routine staff work and treatment compliance. We attempted to perform supportive care for maladjustment by the notice, the fast, and the tube feeding, but there was no improvement. After we added carbamazepine, primidone, and propericiazine (which had been canceled at the initiation of the tube feeding) to the patient's intravenous phenytoin, the symptoms and treatment compliance improved significantly. We concluded that the causes of the patient's irritability were maladjustment and his epilepsy. |
| Keywords | てんかん（epilepsy） 易怒性（irritability） 適応障害（maladjustment） |
| Publication Title | 岡山医学会雑誌 |
| Published Date | 2014-08-01 |
| Volume | volume126 |
| Issue | issue2 |
| Start Page | 133 |
| End Page | 135 |
| ISSN | 0030-1558 |
| language | 日本語 |
| Copyright Holders | Copyright (c) 2014 岡山医学会 |
| File Version | publisher |
| DOI | 10.4044/joma.126.133 |
| NAID | 130004685264 |
| Author | Murakami, Toshi| Takigawa, Nagio| Ninomiya, Takashi| Ochi, Nobuaki| Yasugi, Masaaki| Honda, Yoshihiro| Kubo, Toshio| Ichihara, Eiki| Hotta, Katsuyuki| Tanimoto, Mitsune| Kiura, Katsuyuki| |
|---|---|
| Published Date | 2014-01 |
| Publication Title | Lung Cancer |
| Volume | volume83 |
| Issue | issue1 |
| Content Type | Journal Article |
| JaLCDOI | 10.18926/AMO/55446 |
|---|---|
| FullText URL | 71_5_453.pdf |
| Author | Taniguchi, Akihiko| Miyahara, Nobuaki| Oda, Naohiro| Morichika, Daisuke| Ichihara, Eiki| Oze, Isao| Tanimoto, Yasushi| Ichikawa, Hirohisa| Fujii, Utako| Tanimoto, Mitsune| Kanehiro, Arihiko| Kiura, Katsuyuki| |
| Abstract | Although recent retrospective studies suggested that the use of β-blockers appears to help improve the mortality rate and decrease the rate of exacerbation in chronic obstructive pulmonary disease (COPD) patients with heart failure, the effects of β-blockers on COPD patients without heart failure have not been established. Based on previous reports, we have launched a multicenter, prospective, single-arm phase II study to evaluate the preventive effect of the cardioselective β-blocker bisoprolol in COPD exacerbation, in Japanese individuals with moderate-to-severe COPD who do not have heart failure but do have hypertension requiring the use of medication. The primary endpoint is the rate of mild-to-severe COPD exacerbation. The results of this study will clarify whether bisoprolol can prevent exacerbation in COPD patients without heart failure. |
| Keywords | chronic obstructive pulmonary disease β-blocker bisoprolol exacerbation heart failure |
| Amo Type | Clinical Study Protocol |
| Published Date | 2017-10 |
| Publication Title | Acta Medica Okayama |
| Volume | volume71 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 453 |
| End Page | 457 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| Copyright Holders | CopyrightⒸ 2017 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 29042706 |
| Author | Kurimoto, Etsuko| Miyahara, Nobuaki| Kanehiro, Arihiko| Waseda, Koichi| Taniguchi, Akihiko| Ikeda, Genyo| Koga, Hikari| Nishimori, Hisakazu| Tanimoto, Yasushi| Kataoka, Mikio| Iwakura, Yoichiro| Gelfand, Erwin W.| Tanimoto, Mitsune| |
|---|---|
| Published Date | 2013-01-20 |
| Publication Title | Respiratory Research |
| Volume | volume14 |
| Content Type | Journal Article |
| JaLCDOI | 10.18926/AMO/54603 |
|---|---|
| FullText URL | 70_5_409.pdf |
| Author | Maeda, Yoshinobu| Nishimori, Hisakazu| Inamoto, Yoshihiro| Nakamae, Hirohisa| Sawa, Masashi| Mori, Yasuo| Ohashi, Kazuteru| Fujiwara, Shin-ichiro| Tanimoto, Mitsune| |
| Abstract | Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD. |
| Keywords | Am80 tamibarotene retinoid chronic GVHD steroid-refractory GVHD |
| Amo Type | Clinical Study Protocols |
| Published Date | 2016-10 |
| Publication Title | Acta Medica Okayama |
| Volume | volume70 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 409 |
| End Page | 412 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| Copyright Holders | CopyrightⒸ 2016 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 27777437 |
| Web of Science KeyUT | 000388098700014 |
| Author | Sugiyama, Haruko| Maeda, Yoshinobu| Nishimori, Hisakazu| Yamasuji, Yoshiko| Matsuoka, Ken-ichi| Fujii, Nobuharu| Kondo, Eisei| Shinagawa, Katsuji| Tanaka, Takehiro| Takeuchi, Kengo| Teshima, Takanori| Tanimoto, Mitsune| |
|---|---|
| Published Date | 2014-02 |
| Publication Title | Biology of Blood and Marrow Transplantation |
| Volume | volume20 |
| Issue | issue2 |
| Content Type | Journal Article |
| JaLCDOI | 10.18926/AMO/49251 |
|---|---|
| FullText URL | 67_1_1.pdf |
| Author | Nishimori, Hisakazu| Maeda, Yoshinobu| Tanimoto, Mitsune| |
| Abstract | Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation. Chronic GVHD often presents with clinical manifestations that resemble those observed in autoimmune diseases. Standard treatment is 1-2mg/kg/day of prednisone or an equivalent dose of methylprednisolone, with continued administration of a calcineurin inhibitor for steroid sparing. However, the prognosis of steroid-refractory chronic GVHD remains poor. Classically, chronic GVHD was said to involve predominantly Th2 responses. We are now faced with a more complex picture, involving possible roles for thymic dysfunction, transforming growth factor-β (TGF-β) and platelet-derived growth factor (PDGF), B cells and autoantibodies, and Th1/Th2/Th17 cytokines, as well as regulatory T cells (Tregs), in chronic GVHD. More detailed research on the pathophysiology of chronic GVHD may facilitate the establishment of novel strategies for its prevention and treatment. |
| Keywords | chronic GVHD Th17 Am80 regulatory T cell (Treg) steroid-refractory |
| Amo Type | Review |
| Published Date | 2013-02 |
| Publication Title | Acta Medica Okayama |
| Volume | volume67 |
| Issue | issue1 |
| Publisher | Okayama University Medical School |
| Start Page | 1 |
| End Page | 8 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| Copyright Holders | CopyrightⒸ 2013 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 23439503 |
| Web of Science KeyUT | 000316829900001 |
| Author | Nishimori, Hisakazu| Maeda, Yoshinobu| Tanimoto, Mitsune| |
|---|---|
| Published Date | 2012-12-03 |
| Publication Title | 岡山医学会雑誌 |
| Volume | volume124 |
| Issue | issue3 |
| Content Type | Journal Article |
| Author | Koga, Hikari| Miyahara, Nobuaki| Fuchimoto, Yasuko| Ikeda, Genyo| Waseda, Koichi| Ono, Katsuichiro| Tanimoto, Yasushi| Kataoka, Mikio| Gelfand, Erwin W.| Tanimoto, Mitsune| Kanehiro, Arihiko| |
|---|---|
| Published Date | 2013-01-24 |
| Publication Title | Respiratory Research |
| Volume | volume14 |
| Content Type | Journal Article |
| Author | Soga, Yoshihiko| Yamasuji, Yoshiko| Kudo, Chieko| Matsuura-Yoshimoto, Kaori| Yamabe, Kokoro| Sugiura, Yuko| Maeda, Yoshinobu| Ishimaru, Fumihiko| Tanimoto, Mitsune| Nishimura, Fusanori| Takashiba, Shogo| |
|---|---|
| Published Date | 2009-05 |
| Publication Title | Supportive Care in Cancer |
| Volume | volume17 |
| Issue | issue5 |
| Content Type | Journal Article |
| Author | Iwatani, Kayoko| Takata, Katsuyoshi| Sato, Yasuharu| Miyata-Takata, Tomoko| Iwaki, Noriko| Cui, Wei| Sawada-Kitamura, Seiko| Sonobe, Hiroshi| Tamura, Maiko| Saito, Katsuhiko| Miyatani, Katsuya| Yamasaki, Rie| Yamadori, Ichiro| Fujii, Nobuharu| Terasaki, Yasushi| Maeda, Yoshinobu| Tanimoto, Mitsune| Nakamura, Naoya| Yoshino, Tadashi| |
|---|---|
| Published Date | 2014-07 |
| Publication Title | Human Pathology |
| Volume | volume45 |
| Issue | issue7 |
| Content Type | Journal Article |
